GOLD 2026 COPD Strategy: Mepolizumab Enters the Algorithm
COPD Practice-changing Grade: Moderate
COPD Practice-changing Grade: Moderate
GOLD 2026 adds mepolizumab as a second eosinophil-guided biologic option and refines exacerbation-focused escalation, expanding the pharmacist's role in phenotype-driven COPD care.
GOLD 2023 COPD Report: Major Revisions from the Global Initiative for COPD
COPD Practice-changing Grade: Moderate
COPD Practice-changing Grade: Moderate
The GOLD 2026 update brings significant changes impacting risk stratification, exacerbation management, biologics, and vaccination in COPD care.